Home › Research › Treatments
FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval
U.S. Food and Drug Administration, 2023-07-06
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
The FDA converted lecanemab (Leqembi) from accelerated to full traditional approval after the Phase 3 Clarity AD trial (1,795 patients) confirmed it slowed cognitive decline, making it the first amyloid-targeting antibody to reach full approval for Alzheimer's. The drug carries a boxed warning for ARIA, brain swelling or bleeding that is usually detected on routine MRI and is more common in people with two copies of the ApoE ε4 gene or those on blood thinners.
What this study adds
Evidence grade: Moderate
Lecanemab became the first amyloid-targeting antibody converted to full traditional approval after the Phase 3 Clarity AD trial confirmed it slowed cognitive decline. Its stated limit: Regulatory press release, not primary research; underlying efficacy/safety data captured separately (see clarity-ad-lecanemab-nejm-2023).
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval. (2023). U.S. Food and Drug Administration.
Vancouver
FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval. U.S. Food and Drug Administration. 2023.
BibTeX
@article{study2023-826d45e8,
title = {{FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval}},
journal = {U.S. Food and Drug Administration},
year = {2023}
}
Built from the record alzhub holds for this paper, not looked up. This record has no authors, DOI, so the citation leaves them out. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Based on the Clarity AD Phase 3 trial (n=1,795) showing statistically significant slowing of cognitive/functional decline over 18 months vs placebo
- First amyloid beta-directed antibody converted from accelerated to traditional FDA approval
- Boxed warning for ARIA, including rare but serious brain swelling and seizures; increased hemorrhage risk with anticoagulant use; higher ARIA risk in ApoE ε4 homozygotes
Why it matters
Lecanemab became the first amyloid-targeting antibody converted to full traditional approval after the Phase 3 Clarity AD trial confirmed it slowed cognitive decline. It carries a boxed warning for ARIA, which is more common in people with two copies of the ApoE ε4 gene or those on blood thinners.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designregulatory decision
- Evidence strengthModerate
Limitations
Regulatory press release, not primary research; underlying efficacy/safety data captured separately (see clarity-ad-lecanemab-nejm-2023).
How this study scored 14/100
Regulatory decision — not a study. It scored 14 on the same rubric, which is below the 16 cap we apply to non-peer-reviewed sources. Scored zero for study design, sample size, effect reported, studied in people, randomized / blinded and indexed in PubMed because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 9 of the 66 points we could judge it on, which is 14 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (U.S. Food and Drug Administration) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | Design recorded as “regulatory decision”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 1 / 10 | Regulatory decision — not a study. Named source is a regulator (FDA / EMA / CMS / SEC). |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 0 / 2 | No PubMed ID and no DOI — scores zero (not stated in the record — scored 0) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 9 / 66 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 9 of the 66 points we could judge it on is 14 out of 100. |
| Total | 14 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also in Treatments
196 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.